Industry Supported Sessions

​​​Friday, February 26, 2016

Hall A, 12:30-14:00

Preventing Atrial Fibrillation-Related Strokes with rivaroxaban : Combining Evidence from Clinical Trials and Real Life

Sponsored by 

Chairpersons: John Camm , UK
                       Pierre Amarenco , France

12:30-12:35 - Introduction
                       John Camm , UK
                       Pierre Amarenco , France

12:35-13:15 - Translating data from ROCKET-AF into Real World Experience: 
12:35-12:55 - What are the key learnings from ROCKET-AF trial?​
                       Pierre Amarenco , France
12:55-13:15 - The latest insights from real-life settings in NVAF patients treated
                       with rivaroxaban

                       John Camm , UK

13:15-13:35 - Important practical considerations for the use of NOACs in AF
                       patients - what have we learnt from 5 years of rivaroxaban use

                       Peter VerhammeBelgium

13:35-13:55​Patient management in specific clinical situations : renal
                       impairment, elderly
                       Olivier Hanon, France​

​13:55-14:00 - Conclusion
                       John Camm , UK
                       Pierre Amarenco , France

Keep Me Updated